Heart Failure Protocol
Primary Stack
Core supplements with strongest evidenceEssential for cardiac energy production; levels depleted in heart failure; supplementation improves cardiac function
Anti-arrhythmic, anti-inflammatory, and cardioprotective effects; reduces hospitalizations and mortality
Supporting Stack
Additional supplements for enhanced resultsPrecursor for ATP synthesis; supports cardiac energy production and exercise tolerance in heart failure
Supporting Studies (1)
Transports fatty acids for cardiac energy production; improves exercise capacity and cardiac function
Supporting Studies (1)
Amino acid that supports cardiac contractility, reduces oxidative stress, and has anti-arrhythmic effects
Supporting Studies (1)
Essential for cardiac electrical function; deficiency common in heart failure and associated with arrhythmias
Supporting Studies (1)
Deficiency common with diuretic use; essential for cardiac energy metabolism
Supporting Studies (1)
Supports phosphocreatine energy system; may improve cardiac energy reserves and exercise tolerance
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Heart failure means the heart can't pump blood effectively enough to meet the body's needs. This leads to fatigue, shortness of breath, fluid retention, and limited exercise capacity. The heart muscle in failure is 'energy-starved'—it struggles to produce the ATP needed to contract effectively. While medications (ACE inhibitors, beta-blockers, diuretics) are essential, certain supplements support the heart's energy production and may improve quality of life.
CRITICAL: Heart failure is a serious condition requiring medical management. These supplements are adjunctive to, not replacements for, standard medications. Always coordinate with your cardiologist before starting supplements.
Expected timeline: CoQ10: 4-12 weeks for clinical improvements. Ribose: 2-4 weeks. Thiamine: 2-4 weeks if deficient. These are long-term supportive supplements.
Clinical Perspective
Heart failure (HF) involves impaired ventricular filling or ejection, categorized as HFrEF (reduced ejection fraction ≤40%), HFmrEF (41-49%), or HFpEF (preserved ≥50%). Pathophysiology includes neurohormonal activation (RAAS, SNS), myocardial remodeling, oxidative stress, and mitochondrial dysfunction with impaired ATP production. Standard therapy includes ACE-I/ARB/ARNI, beta-blockers, MRAs, SGLT2 inhibitors, diuretics, and device therapy. This protocol targets cardiac energy metabolism.
CRITICAL: Supplements are ADJUNCTIVE to guideline-directed medical therapy. HF is a serious progressive condition—ensure optimal pharmacologic and device therapy before/during supplement use. Coordinate with cardiology.
Biomarker targets: BNP/NT-proBNP, LVEF, NYHA functional class, 6-minute walk distance, quality of life (KCCQ), serum magnesium, thiamine levels, exercise tolerance.
Protocol notes: GDMT (guideline-directed medical therapy) is foundation: ARNI/ACE-I/ARB, beta-blocker, MRA, SGLT2 inhibitor, diuretics as needed. Device therapy: ICD if LVEF ≤35%, CRT if LBBB and prolonged QRS. Sodium restriction (<2g/day), fluid restriction if hyponatremic. Daily weights to detect fluid accumulation. Cardiac rehabilitation improves functional capacity. Sleep apnea screening and treatment (common comorbidity). Influenza and pneumococcal vaccination. Avoid NSAIDs (worsen HF). Iron deficiency common—IV iron if ferritin <100 or ferritin 100-300 with TSAT <20%. Monitor potassium closely with RAAS inhibitors and MRAs. Advanced therapies: LVAD, transplant evaluation in refractory cases.